Clinical trial · Observational
Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524
Predictive Markers of Response to Pemetrexed (Companion Study to RC0524)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood in the laboratory from patients receiving pemetrexed disodium may help doctors learn more about the effects of pemetrexed disodium on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This laboratory study is looking at blood samples from patients with stage III or stage IV non-small cell lung cancer enrolled in clinical trial MCCRC-RC0524 to determine the effect of pemetrexed disodium on cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gene expression analysis | Genetic | — | UNRESOLVED |
| polymorphism analysis | Genetic | — | UNRESOLVED |
| protein expression analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Activity of pemetrexed disodium (PD) transport and activation enzymes as measured by intracellular content of PD polyglutamates
Secondary outcomes (4)
- measure
- Polymorphisms and gene expression of PD target genes (RFC-1, MRP, folate receptor, FPGS, methylenetetrahydrofolate reductase, methionine synthase, methylthioadenosine phosphorylase, TS, DHFR, GARFT)
- measure
- Polymorphisms and gene expression of genes encoding enzymes involved in the transport, activation, and inactivation of PD
- measure
- Correlation of haplotype-tagged single-nucleotide polymorphisms (htSNPs) and gene expression levels with intracellular levels of PD polyglutamates
- measure
- Correlation of htSNPs and gene expression levels with toxicity and efficacy of PD
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Enrolled in clinical trial MCCRC-RC0524 * Willing to provide blood samples PATIENT CHARACTERISTICS: * No investigator site personnel directly affiliated with the study, or immediate family of investigator site personnel directly affiliated with the study * Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted * Not employed by Eli Lilly (i.e., employee, temporary contract worker, or designee responsible for conducting the study) * Immediate family of Eli Lilly employees allowed, but may not participate at an Eli Lilly facility PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available